Medical treatment of childhood arthritis by Lahdenne, Pekka & Honkanen, Visa
Läkemedelsinformation från Läkemedelsverket, Finland  
Drug information from the National Agency for Medicines, Finland
2|2007
Lääketietoa Lääkelaitokselta
TABU 2.2007 |  15 årgången | 15th Annual volume
Ledare
Läkemedelsanvändning
Ex tempore
Läkemedel för djur
Editorial
ADR news
Drug use
Ex tempore
Läkemedelsmarknadsföring, image och medikalisering
Hannes Wahlroos
Läkemedelsbehandling av barnreumatism idag
Pekka Lahdenne | Visa Honkanen
Marknadsföring av läkemedel 2006
Tiina Kostiainen | Erkki Palva
Äldres användning av psykofarmaka
Anna Koski-Pirilä
Ökningen i läkemedelsförsäljningen avstannade
Tinna Voipio | Pirkko Paakkari
TEO styr och övervakar
Trilostan
Tita-Maria Muhonen
Medicines marketing, image and medicalisation
Hannes Wahlroos
Medical treatment of childhood arthritis
Pekka Lahdenne | Visa Honkanen
A year of pharmaceutical marketing – 2006
Tiina Kostiainen | Erkki Palva
Adverse reactions in Finland 2006
Annikka Kalliokoski | Leena Sommarberg
Biological response modifiers in rheumatoid arthritis: 
a view on their adverse reactions
Radhakrishnan Rajaratnam | Marja Forsell
The elderly and the consumption of antipsychotics
Anna Koski-Pirilä
Drug sales growth at a standstill
Tinna Voipio | Pirkko Paakkari
TEO provides guidelines and supervision
38
39
42
44
48
50
51
53
54
57
59
62
66
69
71
På svenska | Översättning Mats Försskåhl
In English | Translation Mervi Moisander
Läs TABU också vid Läkemedelsverkets web-sidor
http://www.nam.fi/svenska/publikationer/tabu/index.html
Read TABU also on the web
http://www.nam.fi/english/publications/tabu/index.html
TABU 2. 2007 53
In English
Medicines marketing, image and medicalisation
The pharmaceutical industry is described as an inno-
vative and marketing-intensive sector. This is cer-
tainly true. It is also claimed that the more insignifi-
cant the innovation, the more significant and image-
making should the marketing aim to be if the inten-
tion is to sell medicinal products. This statement,
like many others, is based on experience.
One also gets an impression as if  ‘nothing in the
world ever changes’. In the Editorial1 I wrote for this
journal 14 years ago I expressed my wish that the
pharmaceutical industry would rid itself of over-
statements as a consequence of regulations in the EC
Directive issued a year earlier. The pharmaceutical
industry had at the time reformed its own internal
rules regarding regulation and these have been
amended several times since then. From the perspec-
tive of the National Agency for Medicines I had
been – perhaps naively – expecting that there would
be no need to shift the emphasis of drug regulation
on to the monitoring of drug marketing. The review
by Tiina Kostiainen and Erkki Palva of the cases of
regulation within drug marketing is a reflection of a
need for regulation which cannot be ignored.
Despite a certain increase in clarity of the rules
and the environment of the operation, for example
in the contacts between the pharmaceutical industry,
doctors and pharmacists, the problems have moved
elsewhere. Suddenly it seems that the primary aim of
the pharmaceutical industry is to get ‘under the skin’
of the consumer in the marketing of prescription
drugs as well. With disease- and symptomoriented
communications along with good intentions, con-
sumers are drawn towards the pharmaceutical com-
panies’ websites and doctors’ appointments; the
message being that there is a drug for almost any
symptom. Impressions about the everyday need for
drugs in normal life are part of the medicalisation of
society. It may be that the bestknown example of
this is that of the drugs for erection disorders. There
are even others.
I think the development described above may
have several reasons. Competition in the pharma-
ceutical sector has become tougher, which at the
company level usually means cost trimming and/or
increased shrewdness in marketing. Even a quick
gain by way of increased sales may tempt the mar-
keting manager despite the blows necessarily to be
suffered later in the form of rectification measures
or fines applicable internally in the sector.
Another reason is in my view associated with the
management culture and Corporate Governance of
pharmaceutical firms, i.e. good management prac-
tice. In “the good old days”, i.e. when Finland still
had a number of important Finnish pharmaceutical
industry firms, an honour held in high esteem by
company  managing directors, other managers and
owners was not to get trapped into drug marketing
which was against the rules, regulations and good
manners. The situation today, unfortunately, appears
to be such that the main emphasis of enterprise in
many of the drug companies operating in Finland
nowadays lies on drug marketing tricks. The drugs
distributed have, in most cases, been researched, de-
veloped and manufactured abroad.
The third reason may be associated with the phe-
nomenon of empowerment prevailing in health care,
which means that patients and consumers become
fully empowered in matters relating to themselves.
Marketing professionals have obviously realised that
it is also worth focussing marketing efforts on fully
empowered potential patients, who are themselves
expected to influence the decisions about their treat-
ment. According to a recently published dissertation,
the patients often have a big influence on decisions
about prescribing. Patient participation is common
especially in relation to such diseases as have been
to the forefront in the media and advertising.
Whatever the reason may be,  advertising of pre-
scription  medicines to the public is prohibited. Pre-
sentations and marketing of medicinal products
which focus on doctors – within the framework of
the legislation – constitute a task with ample chal-
lenge for all pharmaceutical companies.
1. Wahlroos H: Lääkemarkkinointi uusille urille. TABU
2.1993, 3.
Hannes Wahlroos
Professor, Director General
National Agency for Medicines
Editorial
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Medical treatment of childhood arthritis 
In juvenile rheumatoid arthritis a
persistent inflammation develops
on the synovial membrane. In the
long term the inflammation will
damage the cartilage and eventu-
ally the bone. The process of the
inflammation of the synovial
membrane is similar to that in
rheumatoid arthritis suffered by
adults. With regard to the carti-
lage, the situation for children is
both better and worse than that
of adults: a child’s cartilage is
more easily restored, while dam-
age to cartilage during a period
of growth has an increased ten-
dency to lead to incorrect pos-
tures. Juvenile rheumatoid arthri-
tis (juvenile idiopathic arthritis)
is nowadays divided into seven
groups (Table).
Despite its being an uncom-
mon disease, juvenile rheumatoid
arthritis has, due to the long du-
ration of the condition, serious
implications for our national
health. As many as 19% of the
children who acquired the dis-
ease as late as the 1970s were
never able to enter into working
life, and the rest of the children
often suffered permanently re-
duced functional ability. 
Treatment lines
Nowadays the aim of treatment
of juvenile rheumatoid arthritis is
to obtain remission. This means
invisibility of active arthritis, lack
of symptoms, and normal growth
of the child. Common sense
should nonetheless prevail. Occa-
sional slight pain in the interpha-
langeal joint is not a valid reason
for increasing the medical treat-
ment.
The basic measures for the
treatment of juvenile rheumatoid
arthritis in Finland have for a
couple of decades consisted of
methotrexate and local glucocor-
ticoid injections, including an an-
ti-inflammatory analgesic as nec-
essary. In fact, many of the dis-
eases associated with 1–4 joints
are well managed by local treat-
ments alone (1). However, if
there is a need for frequent local
repeated treatments (more often
than half-yearly) or the response
is inadequate, a small dose of
methotrexate is given as an ad-
junct to treatment. With decades
of experience it is found to be
safe and well tolerated. However,
if a single joint causes persistent
discomfort to the patient, an op-
erative debridement of the syn-
ovial membrane may be consid-
ered. There is nevertheless very
small need for this nowadays.
Hospital in Helsinki for children
and adolescents, responsible for
the treatment of about 400 pa-
tients with juvenile rheumatoid
arthritis, only performs two to
three such operations every year.
In a disease involving more
than four joints, polyarthritis,
treatment with methotrexate is
usually introduced immediately.
If problems of tolerance emerge,
either azathioprine, sulpha-
salazine or leflunomide may be
tried, whereas if their efficacy is
not adequate, there are two al-
ternative approaches: 1) a combi-
nation of several antirheumatic
agents may be used, or 2) the
dose of methotrexate is in-
creased, and oral administration
may be replaced by subcutaneous
administration as necessary. The
latter alternative is more fre-
quently used in children, because
the intake of several drugs by
mouth is often experienced as
uncomfortable and difficult by
both the child and the family. If
this does not give a desired result
either, the use of biological
agents should be considered.
Systemic juvenile rheumatoid
arthritis with generalized symp-
toms still remains a difficult dis-
ease. Fortunately, the disease will
remain permanent in only about
half of those who have contract-
ed it. Arthritis is the long-term
manifestation of the disease in
the majority of patients, but a
small proportion of them exhibit
recurring general symptoms,
Pekka Lahdenne
Senior Lecturer, Head of Department
HUS, Hospital District of Helsinki and Uusimaa
Hospital for Children and Adolescents
e-mail:pekka.lahdenne@hus.fi
Between 150 and 200 children develop juvenile rheumatoid arthritis (nowadays formally called juve-
nile idiopathic arthritis) in Finland every year. Consequently, there are about 5,000 affected sufferers
in the country, of whom perhaps 1,500 are under 16 years of age. Huge leaps forward have taken
place in the treatment. The target at present is to offer the possibility of normal growth, development
and functional abilities to every child affected by the disease. Medication with methotrexate, local
treatment of the affected joints and physiotherapy still remain the cornerstones of the management.
Tumour necrosis factor inhibitors have constituted a crucial reform in the treatment of the most diffi-
cult cases. We commence this paper by first discussing the various treatment lines and then moving
on to the special properties of the various drugs.
Visa Honkanen
Senior Lecturer, Paediatric Rheumatologist
Medical Director
UCB Pharma Oy Finland
e-mail:visa.honkanen@fimnet.fi
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such as rash, pericarditis and
fever. The only effective treat-
ment at the beginning of the dis-
ease is high-dose systemic gluco-
corticoid therapy, the dose of
which is subsequently reduced as
soon as possible once the patient
has become fever-free and the
pericarditis has been resolved.
Once the general symptoms
are managed, the arthritis is
treated in the same way as other
forms of the disease.
In children and adolescents,
seronegative enthesoarthritis
causes inflammation in the at-
tachment area of the tendons to
the bones, i.e. enthesitis,  which
is often painful. This is difficult
to treat with local injections and
there is often a poor response to
antirheumatic agents. Long-term
use of anti-inflammatory anal-
gesics, which is otherwise rare in
juvenile rheumatoid arthritis
nowadays, is sometimes necessary
in these patients.
Disease-modifying anti-
rheumatic drugs (DMARDS) 
The most commonly used drug in
both adult type and juvenile
rheumatoid arthritis is metho-
trexate. Its effect in arthritis is
based rather more on its anti-in-
flammatory properties than on
folic acid inhibition. The initial
dose in children is 15 mg/m2 oral-
ly per week. The dose may be in-
creased up to 30 mg/m2 per week
as necessary. In general, doses in
excess of 20 mg/m2 should prefer-
ably be given as subcutaneous in-
jections, because the absorption
of large doses by mouth is vari-
able. The most common undesir-
able effect is nausea following ad-
ministration of the drug. In some
people the treatment causes pain-
ful ulcers, known as aphthae, in
the mouth. This is nevertheless
rare if the patient’s supportive
treatment consists of folic acid.
Elevation of liver enzyme para-
meters is relatively common. This
is often the result of a concomi-
tant virus infection present. Liver
parameters are monitored as re-
quired at 2 to 8 week intervals.
As the enzyme levels rise the dose
of the drug is decreased and an
interval is interposed in the med-
ication. There is no evidence that
methotrexate would have caused
permanent liver damage in a ju-
venile rheumatoid arthritis pa-
tient. According to an Italian
study, methotrexate achieves an
adequate response in about 80%
of polyarthritis patients, i.e. the
central parameters indicating the
disease are corrected in at least
50% of the patients (2).
Leflunomide is a dihydro-oro-
tate dehydrogenase inhibitor. A
particular target for its effect is
the T cells. It is a drug developed
for the treatment of rheumatoid
arthritis. The dose is 20 mg oral-
ly at intervals of 1–3 days de-
pending on the weight of the pa-
tient. For the treatment of juve-
nile rheumatoid arthritis lefluno-
mide is as effective as methotrex-
ate (3). Its adverse effect profile is
Table 1. Types of juvenile idiopathic arthritis, JIA
1. Systemic  juvenile arthritis (M08.2)
Affects 10% of all children.
The initial symptoms include high fever flaring up 1-2 times a day, rash while the fever is rising,
and often pericarditis.
Polyarthritis, as the condition persists.
2. Oligo-articular/pauciarticular JIA (M08.4)
a) Affects 40-45% of the patients. A typical patient is a girl at the age of playing.
The condition affects 1-4 joints.
General symptoms are rare.
Pauciarticular JIA is often associated with chronic uveitis, which can affect the sight if left un-
treated.
b) The spreading form of the condition: a fifth joint becomes inflamed more than 6 months af-
ter the onset of the condition.
3. Juvenile polyarthritis (seronegative) (M08.3)
Affects 20% of the patients.
The fifth joint becomes affected within less than 6 months from the onset of the condition.
The condition is general in both girls and boys. Due to the large synovial membrane mass, the
condition is often associated with general symptoms, such as tiredness, and occasionally also
feverishness.
The condition may be associated with chronic uveitis.
4. Polyarthritis with a positive rheumatoid factor (M08.0)
Affects less than 10% of the rheumatoid arthritis patients.
A typical patient is a teenage girl.
The disease behaves similarly to the corresponding disease in adults (-> rheumatoid arthritis) at
large, i.e. the risk of erosions is high.
5. Juvenile arthritis in psoriaris (M09.0, L40.5)
Affects 10% of the patients.
The clinical picture is generally mild. Skin symptoms are often minor.
The condition is often characterised by oedema involving the whole digit, i.e. dactylitis.
6. Arthritis in children over 6 years of age, accompanied by inflammation in the at-
tachment area of tendons and bones (enthesitis) or inflammation of the spinal column
or sacral bone joints (M08.4, M08.1)
Affects 10% of the patients.
A typical patient is a teenage boy with spondyloarthropathy (M08.1); if it is arthritis affecting a
couple of joints with enthesitis, it would occasionally be called seronegative enthesoarthritis
(SEA) syndrome. The condition may be associated with both symptomatic acute episodes of
uveitis and asymptomatic chronic uveitis.
7. Other unspecified juvenile arthritis  (M08.9)
Inflammatory bowel disease may also be associated with arthritis. Children mainly exhibit two
types: 1) pauciarticular juvenile arthritis, which may be associated with dactylitis. The symp-
toms vary according to the severity of the bowel disease, 2) a condition similar to that of anky-
losing spondylitis, which does not follow the development of the bowel disease and may con-
tinue to be present in ulcerative colitis once the inflamed intestine is excised.
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very close to that of metho-trex-
ate. Since it is clearly more ex-
pensive than methotrexate and
the experience of follow-up is
not as long term, it is not a pri-
mary drug.
Sulphasalazine is used mainly
in school-age children and as an
adjunct in combination thera-
pies. Its effect is comparable to
that of methotrexate at least in
adults, but it is not as well toler-
ated in children as methotrexate
is (4). Twice daily administration
is also occasionally experienced
as a difficulty. In addition to
stomach complaints the drug
may also cause rash, reduced cell
counts and elevated liver enzym-
es.
The dose of azathioprine is
2–3 mg/kg orally per day. It is
not as effective as methotrexate.
It does not usually cause stom-
ach complaints. In patients with
hereditary 5-thiopurine methyl
transferase deficiency, azathio-
prine may cause a deep and pro-
longed cell deficiency. Azathio-
prine is always a secondary drug
of choice.
Hydroxychloroquine has been
used in the treatment of rheuma-
toid arthritis for a long time. Its
exact mechanism of action is un-
known. The dose is 5–6 mg/kg/
day. The drug is well tolerated.
Undesirable effects include mild
stomach upsets, rash and, occa-
sionally, sleep disturbances. The
effect of the drug is clearly less
potent compared with other an-
tirheumatics. It is mainly used an
adjunct to combination treat-
ments and occasionally for the
maintenance of remission of a lo-
cally treated disease.
Bioligical substances
There are three biological agents
used in the treatment of juvenile
rheumatoid arthritis. They inhib-
it the effect of tumour necrosis
factor (TNF). Etanercept binds
the free factor in the tissue. In-
fliximab and adalimumab are
TNF antibodies. Infliximab is
chimaeric, i.e. the binding sec-
tion originates from a mouse and
the major part of the stem is of
human origin. The drug is ad-
ministered intravenously at 4 to
8 week intervals. The most com-
mon problems include various in-
fusion reactions varying from
rash and a tickly throat to ana-
phylaxis. Adalimumab is a TNF
antibody constructed from hu-
man protein and administered as
subcutaneous injections at 2-week
intervals. In some patients the in-
jection causes a painful lump.
Etanercept is a soluble TNF-bind-
ing protein. It is administered
subcutaneously twice weekly. The
drug is usually well tolerated.
In the Finnish patient material,
there were no great variations ob-
served in the effect of infliximab
and etanercept in paediatric pa-
tients (5). In adults, adalimumab
has been found as effective as
these. The issue is being studied
in paediatric patients. All biologi-
cal agents increase somewhat the
risk of patients contracting in-
flammations. So far, no clear rela-
tionship has been shown between
malignant tumours and drugs
which reduce the effect of TNF.
There are, nevertheless, some re-
ports of malignant lymphatic tis-
sue tumours manifested in adoles-
cents during infliximab therapy
(6). Knowledge about these issues
is increasing along with reports of
long-term follow-up registers.
Anakinra is an interleukin-1
antagonist. It is administered dai-
ly subcutaneously. Its effect in
arthritis is less than that of TNF
drugs. There are nevertheless in-
dications of the fact that anakinra
may work well in some general-
ized autoimmune diseases, such
as NOMID (neonatal onset multi-
system inflammatory disease) and
possibly in juvenile rheumatoid
arthritis with generalized symp-
toms.
It is important to achieve
proper management of juvenile
rheumatoid arthritis without de-
lay. This does not mean, however,
that expensive biological agents
would be the first choice, but
rather that treatment should be
initiated with methotrexate and
local therapies. If the use of a bi-
ological agent is necessary, the
continuation of these costly thera-
pies is likely to be a bigger eco-
nomic problem – since the patient
would in fact cope without them
– than an early introduction of
the therapy. When a biological
therapy is started it is recom-
mended that the patient be told
that it is a drug which is aimed
at controlling the disease, and
that the aim is to manage with
conventional therapies thereafter.
The treatment of juvenile
rheumatoid arthritis has been
revolutionised during the last 10
years. In the past, it was neces-
sary to prepare the family with a
juvenile rheumatoid arthritis suf-
ferer to accept the idea of contin-
uous illness and possible reduc-
tion in functional abilities,
whereas nowadays the argument
always is that the child can be
assured of normal development,
good quality childhood and a
normal work capacity.
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A year of pharmaceutical marketing - 2006
To ensure the appropriateness of
advertising and sales promotion
of medicinal products the Na-
tional Agency for Medicines in
Finland has the task to enforce
the compliance with the legisla-
tion, the Medicines Act and De-
cree. The contents of pharmaceu-
tical marketing are governed in
detail by the Act and the Decree
which stipulate the type of infor-
mation the marketing of medici-
nal products may offer and the
type of material prohibited for
use in that context. The purpose
of the statutes is to promote the
correct and safe use of medicinal
products.
In 2006, a total of 38 cases
involved with the marketing of
medicinal products were brought
forword. About half of the cases
processed were brought to the at-
tention of  NAM through com-
plaints by other companies.
Complaints about drug market-
ing have also been made by indi-
viduals. The processing of some
of the cases have been initiated
by the NAM.
It usually takes several
months to process and conclude
an issue of marketing of a medic-
inal product. The company in-
volved always has an opportuni-
ty to express its views on the
matter under discussion. In the
majority of cases, adjustments in
the company’s marketing will be
made and issues settled with the
pharmaceutical companies by
good mutual agreement. Deci-
sions to ban continuing or re-
newing unlawful marketing, are
as a rule made when there is dis-
agreement on the issue between
the regulatory authority and the
company in question, or if the
decision to ban is otherwise con-
sidered necessary owing to the
nature of the issue. 
Two decisions to ban 
advertising
As a result of two cases concern-
ing marketing of a medicinal
product, NAM made a decision,
enforced by a default fine, to ban
the company’s marketing (Table).
In the advertising of a medicinal
product, Eeze spray gel, pro-
duced by Antula Healthcare Ab,
it was maintained that there were
no adverse effects associated with
the use of the product. In the ad-
vertising targeted at the general
public the product was placed in
a more advantageous position
compared with other products,
an action which is prohibited by
the Medicines Decree. Eeze spray
gel is a locally used anti-inflam-
matory analgesic containing 
diclofenac. The marketing ban
concerning a drug called Lipitor
marketed by Pfizer Oy was the
result of a letter, targeted at
physicians, which referred to a
published study while omitting
the mention of a detail essential
to drug safety. The therapeutic
indication for atorvastatin-con-
taining Lipitor is prevention of
cardiovascular events in patients
considered to be at a high risk of
having a cardiovascular event for
the first time. NAM considered
that the marketing of Lipitor did
not comply fully with the thera-
peutic indication approved for
the product. Pfizer Ltd was re-
quired to deliver a correction of
its marketing material.
Most of the inquiries concern-
ing marketing processed during
2006 involved the marketing of
OTC drugs to the public. A typi-
cal error concerned marketing
material which contained a devi-
ation from the information in the
Summary of Product Characteris-
Tiina Kostiainen Erkki Palva
Senior Pharmaceutical Officer Professor
National Agency for Medicines National Agency for Medicines
Company Product/issue Decision
Antula Healthcare Ab Eeze spray gel / TV-ad-
vertising and marketing
material supplied to
pharmacies
Marketing prohibition, a default fine of EUR 200 000. NAM prohibited Antula Healthcare Ab
from marketing a product with information deviating from the Summary of Product Charac-
teristics or material which is prohibited in accordance with Section  25 b of the Medicines De-
cree.  
Pfizer Ltd Lipitor / Leaflet sent to
doctors with reference to
the results of the SPARCL
Study.
Marketing prohibition, a default fine of EUR 2 million. Correction of marketing. 
NAM prohibited Pfizer Oy from marketing a product using material which deviates from the
approved Summary of Product Characteristics, or which omits mentioning a relevant point re-
garding the medical significance of the product, or refers to clinical trials in a way that gives
an incorrect impression of the final conclusion, extent or importance of the trial.
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tics (SPC). The Medicines Act
and Decree stipulate that all the
information given in marketing
material should comply exactly
with the information in the ap-
proved SPC. Another typical de-
fect in the cases processed con-
cerned the presentation of infor-
mation required in pharmaceuti-
cal marketing, such as the thera-
peutic indication and the advice
for the patient to read the pack-
age information leaflet. Attention
has also been drawn to the fact
that these details essential for the
correct and safe use of the prod-
uct should in the advertising be
presented clearly enough for the
consumer to take notice of them.
Disease awareness informa-
tion increases
According to a definition in the
Medicines Decree, information
on human health and diseases are
not considered pharmaceutical
advertising. Material which aims
to promote the sale, use or pre-
scription of a medicinal product
is considered marketing. Market-
ing of prescription drugs to the
general public is prohibited.
NAM has had its attention
drawn to the increased interest of
pharmaceutical companies in pro-
moting the use of prescription
drugs by disseminating disease
awareness information targeted
at the general public. NAM ex-
pressed its concern in the letter
sent to pharmaceutical companies
at the end of last year. NAM will
this year increasingly concentrate
on the enforcement of compliance
with the prohibition concerning
consumer marketing of prescrip-
tion drugs.
A significant proportion of the
individual marketing regulation
issues processed in 2006 were al-
so concerned with prescription
drug marketing directed at con-
sumers with the aid of medicinal
product leaflets or disease aware-
ness information.
Pharmacies must comply in
their pharmaceutical marketing
with the medicines legislation,
and pharmacies are responsible
for the marketing material they
produce. Three of the cases
processed last year were con-
cerned with marketing material
produced by pharmacies to pro-
mote the sale of OTC drugs.
Marketing directed at pharma-
cy pharmaceutical staff, both
OTC and prescription drug ad-
vertising, should contain all the
information required in advertis-
ing targeted at individuals autho-
rised to prescribe or dispense
drugs. In the distribution of in-
formation and advertising materi-
al produced by pharmaceutical
companies to pharmacy clients it
should be borne in mind that the
requirements concerning advertis-
ing vary depending on whether it
is targeted at the general public
or individuals authorised to pre-
scribe and dispense drugs. For ex-
ample, information on prescrip-
tion drugs intended as instruc-
tions for use for patients may be
interpreted as pharmaceutical
marketing if they are used for
marketing purposes.
Advertising of nicotine prod-
ucts has been moderate 
Since the beginning of February
2006, the sale of nicotine prod-
ucts has been released to the daily
grocery shops and other stores
selling tobacco after having been
available as pharmacy-only prod-
ucts. Bearing in mind that most
of these new entrepreneurs in
pharmaceutical marketing may
not be familiar with the require-
ments regarding marketing laid
down by the medicines legisla-
tion, NAM sent out a letter at the
time of the legislative reform as a
reminder of the rules applicable
to marketing. NAM has been
made aware of only a single case
of a failure by daily grocery store
to comply with the medicines 
legislation associated with the
marketing of nicotine products.
In addition to the OTC prod-
ucts intended to be used in nico-
tine replacement therapy, regis-
trated traditional herbal medici-
nal products and some herbal
medicinal products with market-
ing authorisation can also be sold
elsewhere than the pharmacy.
Since there is no pharmaceutical
drug information available at the
point of sale to assist in the
choice and use of the medicinal
product, in particular, disclosure
of information associated with
the correct and safe use of the
product is of the utmost impor-
tance. Last year NAM intervened
twice in the marketing of herbal
medicinal products.
Recommendations for quality
criteria for sales promotion of
medicines
Recommendations for quality cri-
teria for sales promotion of medi-
cinal products were published by
NAM in the previous issue of
TABU. The compliance with
these recommendations will be
monitored at sales promotion
events. The reason for producing
the quality criteria was not based
on any known or suspected inap-
propriateness in sales promotion
of medicinal products. The crite-
ria are intended as a reminder to
pharmaceutical companies and
professionals taking part in  sales
promotion events of the nature of
these, which is (in accordance
with their definition) the market-
ing of medicinal products. It is al-
so emphasised that, in addition to
complying with individual sec-
tions of the Medicines Act and
Decree, it is relevant to focus on
the purpose of the legislation
governing pharmaceutical mar-
keting – namely, the objective of
correct and safe use of medicines.
In 2006 a total of 1,045 reports
concerning medicinal substances
(other than vaccines) were re-
ceived by the National Adverse
Drug Reaction database in 
Finland. Of the reports, 617 con-
cerned serious adverse reactions
and the number of mortalities
suspected to have resulted from
medical treatment was 28. The
total number of reports was for
the first time in the 2000s less
than that in the previous year; in
2005 the reports totalled 1,131.
Of the reports received from
health care professionals, 20%
were in electronic form, i.e. re-
ports filled in and forwarded on
line through the Internet. 
In 2006 reports were received
on 362 medicinal substances,
most of which only attracted a
couple of reports: 237 medicinal
substances were reported on
twice or even less frequently. The
Table includes the medicinal sub-
stances, which were the subjects
of 10 or more reports. The ma-
jority of these also figured among
the medicinal substances most
frequently reported on in the list
of 2005. Newcomers in the list
include 2 iodine-containing con-
trast media, iopromide and iobi-
tridol, and the other drugs in-
clude duloxetine, fluvastatin, lo-
cal anaesthetic containing adren-
aline and artecaine, olanzapine,
sulphasalazine and aripiprazole.
The Table is by no means a
list of the most dangerous drugs,
and the safety of the medicinal
substances cannot be compared
with one another on the basis of
the number of reports submitted.
The number of drug users varies
greatly, and there may be more
reports received on the ones that
are used frequently than on those
that are used only infrequently.
NAM also advises that, for ex-
ample, any adverse reaction sus-
pected of being associated with
the use of a drug which has been
available on the market for less
than two years, i.e. the use of a
recently introduced drug, should
be reported. This is likely to re-
sult in a greater number of re-
ports being submitted on new
drugs in comparison with old
and well-known drugs. Other
factors may also affect the fre-
quency of reporting, e.g. adverse
reactions reported in the media
or otherwise prominently dis-
cussed may be reported on more
comprehensively than other ad-
verse reactions.
When sporadic adverse reac-
tions mostly reported on are 
examined (excluding vaccines)
skin reactions are those most
common: urticaria was the sub-
ject of 69 and other various types
of rashes of 59 reports. The more
severe skin reactions were signifi-
cantly less frequent, e.g. erythe-
ma multiforme was reported six
times, epidermal necrolysis also
six times and the Stevens-John-
son syndrome two times. Other
common adverse reactions in-
cluded for example nausea and
vomiting (60 reports) and fever
(31 reports).
Contrast media 
Reports received on iodine-con-
taining contrast media totalled
66, mostly on iomeprol (38), io-
promide (12) and iobitridol (10).
Forty-one of the reports were
submitted from the same area re-
flecting local reporting activity.
Of all the reports, 26 were as-
sessed as serious, even though it
cannot be confirmed with cer-
tainty whether the criteria of seri-
ousness were in fact fulfilled in
every report, since the patient
was often transferred from the X-
ray department elsewhere for fol-
low-up monitoring and treat-
ment. The most frequently re-
ported symptoms of adverse reac-
tions included urticaria (37) and
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Medicinal substances most frequently
reported on in 2006 
No
iomeprol 38
clozapine 28
etonogestrel + ethinylestradiol 20
levofloxacin 20
zoledronic acid 19
pregabalin 19
drospirenone + ethinylestradiol 18
duloxetine 18
fluvastatin 16
etoricoxib 15
rosuvastatin 15
terbinafine 15
adalimumab 14
quetiapine 14
simvastatin 14
etanercept 13
infliximab 13
adrenaline + articaine 12
bevacizumab 12
capecitabine 12
iobromide 12
lamotrigine 12
bupropion 11
olanzapine 11
aripiprazole 10
iobitridol 10
risperidone 10
sulphasalazine 10
venlafaxine 10
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other skin symptoms (12), such
as flushing and nausea or vomit-
ing (12). There were also reports
made of more severe symptoms,
such as anaphylactic reaction or
shock (5).
Antipsychotics, antidepres-
sants and bupropione
A total of 78 reports were re-
ceived on antipsychotics (ATC
N05A). Clozapine has over many
years figured at the top of the list
of medicinal substances most fre-
quently reported on with 28 re-
ports being received in 2006. Fif-
teen of these were concerned
with various degrees of leucocyte
deficiencies, three with pul-
monary embolus and one with
deep vein thrombosis. Quetiapine
was reported on 14 times, the
most common adverse reactions
including elevation of liver en-
zymes (4) and malignant neu-
roleptic syndrome (3). Eleven re-
ports were received on olanzap-
ine, and risperidone and aripipra-
zole each received 10 reports.
Tremor associated with the use of
aripiprazole was reported twice,
but apart from that no isolated
adverse reactions which would
have generated several reports
emerged with the use of these
drugs.
Antidepressants (N06A) were
reported on a total of 59 times.
The highest number of reports
(18) received concerned a fairly
recent serotonin and noradrena-
line re-uptake inhibitor, duloxe-
tine, with the additional thera-
peutic indication of female stress
incontinence in addition to the
treatment of depression. In 13 of
the reports some type of adverse
effect targeted at the central ner-
vous system or mental state was
mentioned, such as vertigo,
headache, muscular tics, spasms,
speech disorder, agitation and
confusion; one report concerning
withdrawal symptoms was also
received. Gastrointestinal effects
were reported four times. Ven-
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lafaxine among antidepressants
with its 10 reports retained its
position on the list of 10 drugs
most reported on. The only ad-
verse reactions reported more of-
ten than once were withdrawal
symptoms (3) and hypertension
(2). There were 11 reports re-
ceived on bupropione, six of
which described a rash. The rest
of the adverse reactions were iso-
lated (including confusion, verti-
go, spasms and headache).
Contraceptives
Twenty reports were received on
the etonogestrel and ethinylestra-
diol vaginal ring. Of the isolated
adverse reactions that most com-
monly reported was unwanted
pregnancy (12 cases, one of
which was of a blighted ovum).
Pulmonary embolus was men-
tioned in two reports, both deep
vein thrombosis and sinus throm-
bosis was reported once. 
Contraceptive pills were re-
ported on 36 times, most com-
monly (18 reports) concerning a
product containing drospirenone
and ethinylestradiol. Seven of
these dealt with pulmonary em-
bolus (in addition a deep vein
thrombosis was reported 3 times)
and six were about unwanted
pregnancy. Nine reports were re-
ceived on the levonorgestrel IUD,
six of which concerned pregnancy
(one in the fallopian tube). The
norelgestromin and ethinylestra-
diol contraceptive patch was re-
ported on 9 times (6 being cases
of unwanted pregnancy). 
Statins
A total of 54 reports were re-
ceived on statins, most commonly
on fluvastatin (16), rosuvastatin
(15) and simvastatin (14). The re-
ports were mainly concerned with
adverse effects on muscles, such
as myalgia and elevation of crea-
tinine kinase (22), and one of
them mentioned rhabdomyolysis.
The second most commonly re-
ported reaction was elevated liver
enzymes (15). There were four re-
ports of pancreatitis, two of
which involved users of rosuvas-
tatin and two of fluvastatin; one
of the latter of which also in-
volved atorvastatin as the sus-
pected causative drug.
Selective immunosuppres-
sants, cytostatics and 
monoclonal antibodies
A total of 51 reports were re-
ceived on selective immunosup-
pressants (L04AA), most com-
monly on adalimumab (14), five
of these involved skin reactions;
and tuberculosis was reported
four times. Etanercept attracted
13 reports, three of which con-
cerned malignant tumours, three
were about infections, two men-
tioned psoriasis and one tubercu-
losis. Reports on infliximab (total
of 13 reports) involved infection
four times, melanoma twice, but
no cases of tuberculosis were re-
ported. The rest of the reports de-
scribed isolated adverse reactions.
Capecitabine, a cytostatic, at-
tracted 12 reports, two of which
were about deep vein thrombosis.
In addition, aortic thrombosis
and pulmonary embolus were
both reported once. Sudden death
was a reaction reported three
times, one of the cases also in-
volved coronary artery disease,
and one report concerned ventric-
ular fibrillation. There were 21
reports relating to monoclonal
antibodies, 12 of which were
about bevacizumab, an angiogen-
esis inhibitor used for cancer
treatment. Three of the reports
on bevacizumab described aortic
thrombosis, myocardial infarction
was reported once, and so were
cerebral infarct, sinus thrombosis
and undefined thrombosis. 
Pregabalin and lamotrigine
There have now been 19 reports
received on pregabalin which had
in 2005 reached the list of most
frequently reported medicinal
substances. Nine of these reports
described various central nervous
system and mental reactions. Pe-
ripheral oedema was reported
twice, and so was rash. The rest
concerned isolated adverse reac-
tions. Lamotrigine received 12 re-
ports, nine of which concerned
various types of rashes.
Antimicrobials
The antimicrobials most fre-
quently reported on were, as usu-
al, fluoroquinolones. They at-
tracted 33 reports, 22 of which
concerned Achilles tendinitis or
rupture. Levofloxacin topped the
list of fluoroquinolones with its
20 reports (17 on Achilles ten-
dinitis or rupture). Antifungal
agent terbinafine was the subject
of 15 reports, eight of which con-
cerned loss of or change in taste
perception. Four reports were re-
ceived about skin reactions,
among them one concerning 
erhythema multiforme, and pan-
creatitis was reported once.
Other drugs
Bisphosponates were reported on
23 times, 18 of which concerned
zoledronic acid and osteonecrosis
of jaw.  
There were 17 reports on cox-
ibs, 15 of which concerned etori-
coxib. Five reports mentioned an
adverse cardiovascular reaction
(2 myocardial infarctions). Perfo-
rated gastric ulcer and renal in-
sufficiency were both reported
once.
A local anaesthetic containing
adrenaline and articaine used in
association with dental proce-
dures, attracted a total of 12 re-
ports, 7 in succession of which
were received from the same
source. The most common symp-
toms included palpitations, nau-
sea, vertigo and hypoesthesia.
Anaphylactic reaction was report-
ed once.
Ten reports were received on
sulphasalazine. Leucocyte defi-
ciency and skin reaction were
both reported three times.
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Rheumatoid arthritis (RA) is a
chronic, inflammatory condition
causing systemic illness and
swelling, pain, and destruction of
the joints. Treatment of RA aims
to control pain and inflamma-
tion, reduce joint destruction and
disability, and maintain or im-
prove physical function and qual-
ity of life. The current therapies
include symptomatic relief with
nonsteroidal anti-inflammatory
drugs or simple analgesics and
treatment with disease-modifying
antirheumatic drugs (DMARDs)
to inhibit joint destruction. Glu-
cocorticoids and other anti-
rheumatic drugs are also used to
treat RA.
Although DMARDs are con-
sidered to be first line therapy for
all newly diagnosed cases of RA,
the treatment options of RA have
expanded to include biological
DMARDs. Biological response
modifiers are targeted against the
cytokines believed to be important
in the mediation of inflammation
(tumour necrosis factor, TNF) and
joint destruction (interleukin-1) in
arthritic joints. Infliximab, eta-
nercept, and adalimumab inhibit
TNF-alpha, where as anakinra is
a recombinant inhibitor of inter-
leukin-1. In addition, rituximab, a
chimeric anti-CD20 monoclonal
antibody is also indicated for the
treatment of RA.   
Biological agents may cause a
variety of adverse effects. Safety
data of these new drugs were 
limited before their authorisa-
tion, but have been accumulating
continuously from clinical trials
as well as from postmarketing
surveillance (1). 186 ADR re-
ports were retrieved from the
Finnish Adverse Drug Reaction
database with a cut off date of
15.3.2007 (Table 1).
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Table 1.  Most frequently reported adverse drug reactions  (ADRs) associated with the use bio-
logical substances in rheumatic diseases according  to  System organ classification (SOC)
Drug Number of
patients
Number
of ADRs
Number of
serious
ADRs
System organ classification
(SOC) term
Number of
ADRs
Infliximab 100 139 72 * Infections and infestations 14
Neoplasm benign and malignant 
9
Skin and subcutaneous tissue
disorders 9
Etanercept 47 70 28 Infections and Infestations 12
General disorders and admin-
istration site condition 8
Nervous system disorders 8
Skin and subcutaneous tissue
disorders 8
Adalimumab 32 45 24 Infections and Infestations 8
General disorders and admin-
istration site condition 5
General disorders and admin-
istration site condition 5
Anakinra 4 6 3 different SOCs
Rituximab** 3 5 3 different SOCs
Total 186 265 130
In Finland infliximab and other biological drugs have been used since 1999 in the treatment of
rheumatoid arthritis.  According to the national sales statistics, the consumption of infliximab in
2006 was 0.31, etanercept 0.22, adalimumab 0.19 and of anakinra 0.01 DDD/1,000 inhabitants/day.
Safety data of these new drugs were limited before their authorisation, but have been accumulating
continuously. 186 reports including 265 ADRs were reported to the Finnish Adverse Drug Reaction
database until 15.3.2007. Infections and general disorders and administration site reactions are the
most frequently reported adverse reactions.
* Including 5 fatal cases
** ADRs in RA patients.
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Injection site and infusion 
reactions 
Injection or infusion reactions
are the most common adverse
effect of biological agents. 12%
of reported ADRs to the NAM
were injection site and infusion
reactions (Table 2). Injection site
reactions associated with subcu-
taneously administered drugs
(adalimumab, etanercept and
anakinra) consist of erythema
and induration limited to the in-
jection site. These reactions are
mild and require no specific ther-
apy other than symptomatic relief
by antihistamine or corticoster-
oid. 
Infusion reactions including
anaphylactic reactions are the
most common adverse effect as-
sociated with intravenous inflix-
imab and rituximab administra-
tion. These reactions are transient
and can be treated by decreasing
infusion rate and, if needed, by
antihistamine or intravenous cor-
ticosteroid. Prior to rituximab
infusion, patients should receive
methylprednisolone to decrease
the acute infusion reactions. 
Infections
Although the risk of infection is
increased in the rheumatic dis-
eases, an additional risk of seri-
ous infections has been reported
in some clinical trials with anti-
TNF therapy. Postmarketing sur-
veillance and meta-analysis have
also suggested an enhanced risk
of infections in patients treated
with TNF-antagonists in RA (1,
2). Also the risk of serious infec-
tions has been shown to be in-
creased in patients treated con-
currently with anakinra and eta-
nercept. 
Recently published results
from the British Society for
Rheumatology Biologics Register
indicated that in patients with
active RA, anti-TNF therapy was
associated with increased risk of
skin and soft tissue infection but
not with overall serious infection
compared with DMARD treat-
ment after adjustment for base-
line risk. 
TNF alpha is a key compo-
nent of host defence against My-
cobacterium tuberculosis, espe-
cially in the formation of gra-
nulomas. Inhibition of TNF ap-
pears to increase the risk of M.
tuberculosis and other agents
causing granulomatous diseases,
such as listeriosis and histoplas-
mosis. Most of the TBC cases
occured within a relatively short
time after the exposure to the
drugs, implicating reactivation of
the latent disease rather than
newly acquired primary disease
by the biological agents. EMEA
made a public statement on in-
fliximab in 2000 after reviewing
28 cases of infection TBC associ-
ated with infliximab therapy. In
general, pre-treatment screening
of patients for latent tuberculosis
and greater vigilance for bacteri-
al and opportunistic infections
are recommended in patients
treated with anti TNF agents.
Patients requiring surgery should 
T a b l e  2 .  I n j e c t i o n  s i t e  -  a n d  i n f u s i o n  r e a c t i o n s
Infliximab Etanercept Adalimumab Anakinra Rituximab
Allergic reaction and 
rash 12 3 1
Anaphylactoid reac-
tion 4 2
Anaphylactic reaction
and shock 2+2 1
Injection site reaction
3 1
T a b l e  3 .  I n f e c t i o n s
Infliximab Etanercept Adalimumab Anakinra Rituximab
Pneumonia
2 1
Pneumocystis carini
pneumonia 2
(Pulmonary infiltra-
tion) 2 1 1
(Pericarditis)
2 1
(Pleuritis)
1
Arthritis bacterial/
septic 2 2
Encephalitis herpes
1
Cytomegalovirus 
infection 2
Herpes zoster 
1
Varicella zoster
1
Infection
2 1
Infection TBC
10 2 8
Sepsis
1 2
Erysipelas
1 1
Infection mycobac-
terium avium 1
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be closely monitored for infec-
tions.
In the database of NAM there
were 20 cases of infection TBC
associated with the biological
agents. Latency varied in these
cases from one to 27 months.
Other majority of the main reac-
tions related to infection are sum-
marised in the Table 3.
Malignancies
Safety concerns on a possible in-
creased risk of cancer, particular-
ly hematologic malignancies,
have emerged recently, although 
evidence is conflicting. In clinical
trials, increased incidence of lym-
phoma and non-melanoma skin
cancers have been reported in pa-
tients treated with TNF inhib-
itors. On the other hand, the inci-
dence of other types of malignan-
cies in patients treated with TNF
antagonist was found to be simi-
lar to or lower than that observed
in the general population (3). A
recent study indicated that users
of biologic agents are unlikely to
have a substantial increase in the
risk of hematologic malignancies
and solid tumors as compared
with methotrexate users (4).  Giv-
en the complexity of duration
and severity of disease and the
relatively short duration of expe-
rience with biological agents, it
has not been established  whether
these agents modify the risk of
malignancies. However, caution
should be exercised when consid-
ering anti-TNF therapy for pa-
tients with a history of malignan-
cy, or when considering continu-
ing treatment in patients who de-
velop a malignancy. A signal for
increased incidence of smoking
related malignancies with inflix-
imab exposure was detected in
2005 by EMEA in patients with
moderate to severe chronic ob-
structive pulmonary disease and
heavy smoking history. The SPC
for infliximab was updated ac-
cordingly. All the malignancies re-
ported to NAM associated with
TNF antagonists are listed in
Table 4.
Congestive heart failure
Higher incidences of hospitalisa-
tion and mortality for worsening
heart failure were seen in patients
treated with infliximab, especially
during use of high doses. Worsen-
ing of heart failure has also been
reported in patients treated with
adalimumab and etanercept. In-
fliximab and adalimumab are
contraindicated in patients with
moderate or severe heart failure.
In the NAM database, only one
case was identified for heart fai-
lure in patients using biological
drugs. In this case infliximab ag-
gravated heart failure. 
Hematological effects
Hemotologic adverse events in-
cluding clinically significant cy-
topenia have been infrequently
reported with biological agents
(Table 5). Cases with pancytope-
nia and aplastic anaemia, some
with fatal outcome have been re-
ported rarely in patients with RA
treated with etanercept. If blood
dyscrasias are confirmed the ther-
apy should be discontinued. 
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T a b l e  4 .  M a l i g n a n c i e s
Infliximab Etanercept Adalimumab Anakinra Rituximab
Breast neoplasm ma-
lignant 1 1
Carcinoma hepato-
cellular 1
Lymphoma
1
Melanoma
1 1
Meningioma
1
Acute/chronic
myeloid leukaemia 2
Ovarian cancer 
1 1
Pancreas cancer 
1
Prostate cancer 
1
T a b l e  5 .  H e m a t o l o g i c  a d v e r s e  e f f e c t s
Granulocytopenia
1
Leucopenia
2
Neutropenia
1 1
Thrombocytopenia
1
Pancytopenia
1 1
T a b l e  6 .  H e p a t i c  a d v e r s e  e f f e c t s
Infliximab Etanercept Adalimumab Anakinra Rituximab
Hepatitis 2 1
Hepatic enzymes 
increased 7 1
Liver fatty 1
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Hepatic reactions
A review of occurrence of hepat-
ic adverse effects in clinical trials
and post marketing data revealed
that rare cases of jaundice and
non-infectous hepatitis are asso-
ciated with biological agents.
Sporadic cases of liver failure re-
sulting in liver transplantation or
death have occurred. Reactiva-
tion of hepatitis B occurred in
patients receiving infliximab who
were carriers of this virus. 12 he-
patic adverse effects have been
reported to the NAM registry
(Table 6).
Drug induced lupus erythe-
matosus and vasculitis
Approximately half of inflix-
imab-treated patients in clinical
trials who were antinuclear anti-
body (ANA) negative at baseline
developed a positive ANA during
the trial. Clinical signs consistent
with a lupus-like syndrome have
developed rarely. In the NAM
registry, two LE rash cases, one
with infliximab and the other
with adalimumab were identi-
fied. One case with antinuclear
factor test positive was reported
in a patient receiving infliximab.
Three cases of vasculitis were re-
ported in 2 patients with inflix-
imab and in one patient with
adalimumab. 
Neurological adverse effects
TNF-alpha inhibitors have been
associated with rare cases of
clinical symptoms and or radi-
ographic evidence of demyelinat-
ing diseases suggestive of multi-
ple sclerosis or optic neuritis. A
careful risk benefit evaluation is
recommended when prescribing
these drugs to patients with pre
existing demyelinating disases. In
the NAM registry, one case of
demyelination was identified in a
patient treated with etanercept.
Skin reactions
The published data collected
over a 5-year period from the
National Register of Biological
treatment in Finland (ROB-FIN)
indicated that 35 % of the re-
ported 308 reactions were skin
reactions (5). In the NAM reg-
istry, one serious urticaria case
associated with infliximab and 9
non serious rash reactions, of
which 6 with etanercept, 1 with
infliximab and 2 with adalimum-
ab were identified.    
Conclusions
Although biological medicines for
rheumatic diseases have now
been on the Finnish market for
more than 7 years, the full spec-
trum of their safety risk has not
yet to be fully elucidated. 
After their authorisation sev-
eral new safety concerns have
arisen, involving mycobacterial
and opportunistic infections, cy-
topenias, lymphoma, drug-in-
duced lupus, demyelinating dis-
eases, congestive heart failure and
hepatotoxicity. Regarding these
safety issues, EMEA has drawn
attention to precautionary mea-
sures and, accordingly, prescrib-
ing and patient information for
these drugs have been amended
to include these new safety data
in SPCs. 
NAM has received 186 re-
ports including 265 ADRs associ-
ated with these biological medi-
cines in the treatment of RA.
Most of reported cases have clas-
sified as serious. 
Some of ADR cases remain
unreported. To further analyse
their impact on patient safety,
widespread post-marketing phar-
macovigilance and monitoring of
these biological agents is neces-
sary. The clinician must weigh
the therapeutic benefits of these
drugs against adverse effects. Pa-
tients should be evaluated care-
fully for the risk of adverse ef-
fects by regular clinical assess-
ments. 
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The elderly and the consumption of antipsychotics
An increasing proportion of psy-
choleptics is used outside inpa-
tient facilities: in 2005, 83% of
antipsychotic and 93% of antide-
pressant drugs were consumed in
outpatient care in Finland [1].
The use of psycholeptics in out-
patient care was commonest in
the oldest age groups: reim-
bursable antidepressants were
most often purchased by 85–94-
year-olds (12% of men and 17%
of women) [2] and reimbursable
antipsychotics by 90-year-olds
and older (8.6% of women and
7.2% of men), followed by
80–89-year-olds (6.5% of
women and 5.3% of men) [3].
The use of anti-dementia drugs is
also commonest among the elder-
ly [4] and has rapidly increased:
both the consumption of anti-
dementia drugs and the number
of entitlements to refunds has
shown a 10-fold increase from
1999 to 2005 [1, 5].
The use of psycholeptics in
the elderly has been investigated
in several Finnish studies, but a
more accurate picture is warrant-
ed on the home-dwelling elderly,
whose primary illness has not
consisted of a severe mental dis-
order. This survey was undertak-
en to give a comprehensive pic-
ture of the outpatient use of an-
tipsychotics and antidepressants
in the over 74-year-olds. Use of
anti-dementia drugs was incorpo-
rated in the study, because in ear-
lier surveys the use of psycholep-
tics has differed between the de-
mentia sufferers and those with-
out dementia [6, 7]. Data from
the special refund register were
used to exclude from the survey
persons with mental handicap,
severe psychosis or other severe
mental disorders.
Methods
The subject data were collected
from the files of the Finnish So-
cial Insurance Institution. The
prescription register was used to
identify individuals who had in
2005 been refunded for antipsy-
chotics (N05A), antidepressants
(N06A, N06C) or anti-dementia
drugs (N06D). A 50% sample of
the individuals was taken. The
drug purchase details on their
psych-oleptics purchases in 2005
were extracted from the prescrip-
tion register. Their entitlement to
special refunds on psycholeptic
and anti-dementia drugs was
checked in the refund register. 
In this survey, psycholeptics
refer to antipsychotics (ATC class
N05A), anxiolytics (N05B), hyp-
notics and sedatives (N05C), an-
tidepressants (N06A) and psyc-
holeptics and psychoanaleptics in
combination (N06C). However,
drugs having main indications
other than psychosis (lithium,
prochlorperazine and dixyrazine)
were omitted from the survey of
antipsychotics (N05A). Users of
class N06C drugs alone were few
and consequently excluded from
the survey.
The survey data did not cover
the entire outpatient consump-
tion, because the reimbursement
system does not include all psyc-
holeptic products, strengths and
package sizes. The drug con-
sumption covered by the survey
data was therefore compared
with the drug sale statistics from
NAM. The survey data covered
on average over 90% of the out-
patient consumption of antipsy-
chotics and antidepressants and
about 86% of the antidementia
drug consumption. The outpa-
tient consumption of anxiolytics
(N05B) was covered by about
47% and hypnotics and sedatives
(N05C) by 33%. However, mida-
zolam and triazolam were not re-
funded and thus not included at
all.
From the sample described
above, only those elderly persons
who did not in 2005 or earlier
have a special refund entitlement
for psycholeptics were eligible for
this survey. The final survey data
therefore covered 72% of the el-
derly antipsychotics users and
92% of the antidepressants users.
Of the reimbursed antipsychotic
and antidepressant consumption
by the elderly, the survey data
covered 51% and 90%, respec-
tively. The final data included
30,474 individuals split up into
sub-groups for each drug group
(Figure).
Results and conclusion
The survey data suggest that of
the entire elderly population in
Finland in 2005 about 4% used
antipsychotics, about 11% used
antidepressants and about 5%
used anti-dementia drugs, with
basic refund entitlement. It is
conspicuous that as much as half
Anna Koski-Pirilä
PhD, Senior Researcher
Planning for Pharmaceutical Policies
National Agency for Medicines
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of the reimbursed antipsychotic
consumption in the elderly was
covered by basic refund entitle-
ment. Special refund entitlement
requires severe and long-term ill-
ness. In the case of antipsy-
chotics, the most common spe-
cial refund entitlement 112 re-
quires severe psychosis or other
severe mental capacity disorder.
Therefore it is presumed that
half of the reimbursed antipsy-
chotic consumption in the elderly
is used for the treatment of less
pronounced and more short-term
symptoms.
Some of the elderly have in
the course of the study year
bought psycholeptics of many
different drug groups (Figure),
which, owing to the length of the
survey period, does not necessar-
ily mean their concomitant use.
These psycholeptics consumer
groups without special refund
entitlement included elderly
women more often than men,
which was also the case in rela-
tion to the entire elderly popula-
tion studied as 5-year age
groups. The use of the above
drug groups became more com-
mon in both sexes with increas-
ing age; the use of antidepres-
sants and anti-dementia drugs
was most common in the group
of 85–90-year-olds, and the use
of antipsychotics in the group of
90–94-year-olds in both sexes.
Elderly women using antipsy-
chotics also used antidepressant
medication more often than men.
About half of the elderly using
antipsychotics or antidepressants
also used anxiolytics or hyp-
notics. Moreover, women using
antipsychotics had purchased
anxiolytics or hypnotics more
often if they were on anti-demen-
tia therapy. Elderly persons using
antidepressants were twice as 
often also using anxiolytics, hyp-
notics or antipsychotics if they
were on anti-dementia therapy. 
Among those using anti-
dementia drugs, 50% of men
and 40% of women had not ac-
quired other reimbursable drugs
in the ATC classes N05 and
N06. An average of 30% had
used antidepressants, the propor-
tion of women (34%) being
higher than that of men (23%).
About 20% had used antipsy-
chotics and 32% had used anxi-
olytics or hypnotics with basic
entitlement to a refund.
Drugs most commonly used 
Among the elderly using antipsy-
chotics without entitlement to a
special refund, 39% used risperi-
done, 28% quetiapine, 11%
melperone and 10% haloperidol.
Haloperidol, owing to its having
few anticholinergic effects, and
melperone, owing to its having
few extrapyramidal adverse ef-
fects have been recommended
for the elderly among the con-
ventional antipsychotics [8]. 
The most commonly used an-
tidepressant without entitlement
to a special refund was citalo-
pram, which had been pre-
scribed to 43% of the elderly
who were on antidepressant
therapy. Mirtazapine was the
second (24%) and escitalopram
the third most commonly used
(16%). The next most common-
ly used antidepressants were the
tricyclic amitriptyline and dox-
epin, even though tricyclic anti-
depressants should be avoided in
the elderly owing to their anti-
cholinergic effects [9]. However,
amitriptyline in particular is also
used for the treatment of chron-
ic, especially neuropathic pain,
albeit in smaller doses than in
antidepressant use.
Risperidone was relatively
more common among antipsy-
chotics used by those elderly
who were on anti-dementia ther-
apy (48%) versus those who
were not (36%). This complies
with the recommendations, as
risperidone is the only antipsy-
chotic having the therapeutic in-
dication of treatment of severe
behavioural disorders associated
with dementia (with certain re-
strictions) [10].  Citalopram was
relatively more common among
antidepressants used by those
who were on anti-dementia ther-
apy (52%) versus those who
were not (43%). This was also
in line with recommendations, as
3 364
5 189
Antidepressants
Antipsychotics
Anti-dementia drugs
20 750
7 056
9 121
1 171
1 887
634
2 127
16 201
Over 74-year-old users of psycholeptics and anti-dementia drugs without
special refund status (a 50% sample in 2005).
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serotonin re-uptake inhibitors are
the primary choice in the treat-
ment of depression in dementia
patients [10]. As anti-dementia
drugs should not generally be
used concomitantly with potent
anticholinergics [10], compliance
with recommendations was also
brought about in the situation
where the proportion of per-
phenazine and levomepromazine
among the antipsychotics and the
proportion of amitriptyline and
doxepin among the antidepres-
sants used by elderly anti-demen-
tia drug users were smaller when
compared with other elderly per-
sons.
Drugs with a long half-life
The frequency of use of anxiolyt-
ics, hypnotics and sedatives was
not studied extensively due to
scanty prescription data. Special
attention was, however, drawn to
the use of benzodiazepines with
long-term effect (diazepam, chlor-
diazepoxide, nitrazepam), since
benzodiazepines with a long half-
life should not, as a rule, be used
in the elderly owing to the risk of
long-term sedative and cumula-
tive effects [11].
Among the elderly in these
survey data, 5% of the antide-
pressant users, 4% of the antipsy-
chotic users and 2% of the anti-
dementia drug users had also
used benzodiazepines with a
long-term effect entitling them to
a basic refund. In reality, the use
of benzodiazepines with a long-
term effect can be assumed to be
more prevalent, because the data
only covered just over a third
(36%) of their consumption in
outpatient care.
Fluoxetine, a serotonin re-up-
take inhibitor with a long half-
life, should also be avoided in the
elderly [11]. In this sample, 919
(4%) of the elderly on an antide-
pressant therapy entitling them to
a basic refund had used fluoxe-
tine. Consequently, in the whole
country almost 2,000 elderly pa-
tients, i.e. about half a percent of
the elderly population, were using
fluoxetine. However, its use in
the elderly appears to have di-
minished since 1999, when, cal-
culated on the basis of annual
purchases, fluoxetine used to be
the second commonest antide-
pressant among the elderly [12].
Conclusions
In 2005, about half the reim-
bursed antipsychotic use and
90% of the reimbursed antide-
pressant use in the elderly were
acquired without special refund
entitlement. It most likely indi-
cates their use in the treatment of
other than severe and long-term
mental disorders. Moreover, some
psycholeptic use contrary to the
recommendations occurred
among the elderly in the survey
data. The psycholeptic medica-
tion among the elderly on anti-
dementia drug therapy differed
slightly from that among the rest
of the elderly in the direction of
the recommendations.
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The drug wholesale value in
2006 amounted to 1.7 billion
euros in Finland, which is about
half a percent less than in 2005.
The pharmacy sale value de-
creased (by 3%). There was a
further increase in the sales to
hospitals (7%).
Cuts in the drug wholesale
prices, generic substitution, price
competition and the Medicines
Act reform at the beginning of
2006 have had a negative influ-
ence on drug sales value. For ex-
ample, the consumption of sim-
vastatin increased by almost
40%, but its sales value dropped
by 20%. The consumption of
ramipril increased by 10%, but
the sales in wholesale prices were
60% lower than the previous
year.
The largest groups
Drugs with an effect on the ner-
vous system (N) remained the
largest drug group by sales. The
second largest group by sales was
that of antineoplastics and im-
munomodulating drugs (L). The
largest group according to the
doses used daily, drugs used for
the cardiovascular system (C),
was the third largest group ac-
cording to its sales figures (Fig-
ure 1).
The list of the ten most com-
monly used drugs showed hardly
any changes in comparison with
the previous year. Ibuprofen was
moved from second place to fifth
following simvastatin, ramipril
and furosemide, each of which
were moved one stage upwards
(Table 1). 
Atorvastatin at wholesale
prices kept its position as the
best sold drug even though its
sales decreased by 20% and its
consumption by 11% (Table 2).
Tinna Voipio
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National Agency for Medicines
Pirkko Paakkari
Chief Medical Officer 
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Drug sales growth at a standstill
T a b l e  1 .  T h e  1 0  m e d i c i n a l  s u b s t a n c e s  m o s t  c o m m o n l y  u s e d  i n  2 0 0 6
ATC Code EUR million Change  in % DDD/1,000 Change  in % 
inh/day
B01AC06 acetylsalicylic acid antithrombotic prophylactic 7,8 -16,7 % 83,76 -20,6 %
C10AA01 simvastatin cholesterol-lowering drug 7,4 -19,9 % 56,33 39,2 %
C09AA05 ramipril drug for cardiac disorders 3,1 -59,6 % 43,56 10,1 %
C03CA01 furosemide drug for cardiac disorders 4,6 -1,8 % 34,86 4,0 %
M01AE01 ibuprofen anti-inflammatory analgesic 16,2 -35,5 % 32,89 -19,7 %
C10AA05 atorvastatin cholesterol-lowering drug 33,5 -19,5 % 29,22 -11,0 %
N05CF01 zopiclone hypnotic and sedative 4,3 -15,4 % 26,82 -0,5 %
C09AA02 enalapril drug for cardiac disorders 2,1 -11,1 % 25,71 -3,8 %
C08CA01 amlodipine drug for cardiac disorders 9,3 -52,6 % 24,40 3,2 %
C07AB07 bisoprolol drug for cardiac disorders 7,5 2,2 % 24,24 6,7 %
Ta b l e  2 .  10  m e d i c i n a l  s u b s t a n c e s  m o s t  c o m m o n l y  s o l d  a t  w h o l e s a l e  p r i c e s  i n  2 0 0 6
ATC Code EUR million Change  in % DDD/1,000 Change  in %
inh/day
C10AA05 atorvastatin cholesterol-lowering drug 33,5 -19,5 % 29,22 -11,0 %
N05AH03 olanzapine antipsychotic 33,1 8,2 % 4,90 13,1 %
R03AK06 salmeterol och fluticasone anti-asthmatic 25,4 -0,5 % 8,23 6,2 %
J01DC02 cefuroxime anti-microbial 24,4 36,5 % 0,59 7,4 %
N07BA01 nicotine nicotine replacement therapy 21,5 23,0 % 6,37 19,6 %
N05AH04 quetiapine antipsychotic 20,4 15,9 2,59 23,7 %
N05AX08 risperidone antipsychotic 19,5 7,8 % 2,46 9,9 %
A02BC05 esomeprazole drug for acid related disorders 18,8 -0,6 % 9,70 23,9 %
L04AA11 etanercept antirheumatic 16,8 22,0 % 0,22 28,4 %
M01AE01 ibuprofen anti-inflammatory analgesic 16,2 -35,5 % 32,89 -19,7 %
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Since October 2006 refund for
atorvastatin has been granted on-
ly when the prescription con-
tained a doctor’s specification
about a lipid metabolism disorder
difficult to manage. Amlodipine,
which was dropped from the list
of ten best sold drugs, had occu-
pied the fifth place the previous
year. A new antirheumatic agent,
etanercept, was included in the
list, with a consumption of only
0.2 DDD/1,000 inhabitants/day.
The most commonly used
drug was acetylsalicylic acid indi-
cated for prevention of arterial
thrombosis with a consumption
rate of 84 DDD/1,000 inhabi-
tants/day. Consequently about
8% of the population was using
this drug. The consumption was
17% lower compared with the
year 2005. Some of the drop in
the sales value is explained by the
stipulation in the Medicines Act
reform at the beginning of 2006
of a ban on targeted reduced
prices. At the end of 2005 phar-
macies filled their stocks by buy-
ing popular products, the sales of
which were lower than usual at
the beginning of the year (Figure
2). A similar apparent drop in the
annual consumption owing to
stockpiling is also seen in the case
of ibuprofen with reduced con-
sumption by 20%.  
The total sales of OTC drugs
remained 18% lower compared
with the previous year. This is al-
so explained to a large extent by
the considerable stockpiling that
had taken place at the end of that
previous year.
Nicotine products
Since the beginning of February
2006 nicotine products have also
been allowed to be sold from re-
tail shops, petrol stations and
kiosks. The sale of the products
requires authorisation obtainable
from the municipality. Pharma-
cies received 70% of the nicotine
products wholesale and about
30% was sold direct to retailers,
kiosks and petrol stations.
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Figure 1.  Drug sales in Finland according to ATC code  in 2006 (total  in wholesale
prices  
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Figure 2.  Sale of OTC  drugs in Finland quarterly in years 2005–2006.
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TEO provides guidelines and supervision
In English
The National Authority for
Medicolegal Affairs in Finland,
TEO, promotes the quality of
services and the use of legal safe-
guards in social and health care.
TEO has frequently been
called the health care licensing
and supervisory authority. We do
indeed grant various licences. As
regards professional practice, we
legalised and granted licences for
over 6,000 health care profes-
sionals last year alone. We also
granted to health care profes-
sionals over 7,000 rights to use
certain titles. The health care
professionals register, Terhikki,
contains the records of more
than 330,000 professionals. The
responsibilities of TEO go be-
yond the registering of profes-
sionals. The register continuously
receives requests for various cer-
tificates, intended for job appli-
cations, for example, as well as
requests for details of the blame-
less conduct of health care pro-
fessionals. A lot of work for
TEO is generated by health care
professionals arriving from out-
side the EU countries and aiming
to work in Finland, because
qualifications obtained by them
need to be compared with quali-
fications required in our country,
and the likelihood of their being
able/allowed to work as physi-
cians in Finland is examined.
We also issue other types of
authorisations. Authorisation to
abort a pregnancy must in cer-
tain cases be applied for from
TEO. These authorisations are
discussed by a board specialising
in issues of abortion and sterili-
sation, with meetings every Tues-
day and Thursday. Last year we
issued a total of 889 authorisa-
tions to abort a pregnancy. Steril-
isation authorisations almost be-
long to history nowadays, but
isolated cases are still authorised
from time to time.
An Act on fertility treatment
will come into force in Septem-
ber. According to the Act, giving
treatment and storing spermato-
zoa and ova, as well as embryos
are subject to licence. The
records of these are also main-
tained and licences granted by
TEO.
What about the supervision?
Since its inception TEO has is-
sued guidelines about, and super-
vised the work of, individual
health care professionals, mainly
by way of complaints and vari-
ous reports. The complaints are
made by the patients themselves
or their relatives. TEO will deal
with them when they concern
suspected errors of treatment re-
sulting in mortality or severe in-
jury. Other complaints are dealt
with by the Provincial State Of-
fices. Last year TEO handled
267 complaints. Reports on
health care professionals are
made, for example, by pharma-
cies, employers, legal courts or
the police. For example, a phar-
macy may report that a certain
physician prescribes rather high
amounts of CNS drugs, and
TEO would consequently investi-
gate the appropriateness of the
doctor’s actions. Or it may be
the case that an employer sus-
pects the work ability of a doc-
tor or a nurse owing to e.g. ill-
ness or alcohol abuse; these are
also issues examined at TEO.
Last year a total of 660 com-
plaints, reports and requests for
statements relating to the super-
vision of health care profession-
als were received by TEO. Ten
years earlier less than half as
many were received, under 300.
While TEO supervises health
care professionals it also at the
same time gives them guidelines.
Each case of supervision is thor-
oughly investigated together with
experts, and the professionals in-
volved and possibly also their su-
periors receive as necessary a no-
tification which will, for exam-
ple, focus on the discrepancies of
their work and place emphasis
on the correct way of working.
Solutions to complaints are an-
nually collected into a short
summary which is published and
sent to the rank and file health
care workers and it is hoped that
it will serve as a form of precau-
tion for health care units in their
work.
The faulty or reprehensible
work or action of a health care
professional is not always his or
her fault alone. The circum-
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stances may be influenced, for ex-
ample, by poorly designed perfor-
mance practices at a hospital,
which, combined with work over-
load, expose the professional to
making errors. It is in these cir-
cumstances rather unfair that in-
dividual employees alone be at
the receiving end of complaints. 
This situation was changed in
September last year, when the
provision of guidelines and super-
vision were extended to cover
health care units as well. TEO
was also made responsible for co-
ordinating and harmonising the
health care guidelines given and
supervision provided by social
services and health departments
of the Provincial State Offices.
The aim is that people in the var-
ious parts of Finland should re-
ceive equal treatment and that
complaints about treatment
should be processed following
uniform principles in every
province.
In accordance with its extend-
ed job description, TEO will in
future attach increased impor-
tance to prophylactic work and
the provision of guidelines, which
will improve the safety and quali-
ty of health care and diminish in-
appropriate actions and thereby
hopefully also the volume of
complaints and other appeals.
The focus areas in guidelines
and supervision chosen by us for
this year include e.g. making sure
that treatment guarantees work,
together with medical treatment,
harmonisation of the manage-
ment of licences in private health
care, and elderly care. We work
in close collaboration with the
Provincial State Offices and make
quarterly joint inspections, also in
public, of the results of our ef-
forts.
TEO is also an authority
which grants state subsidies. Last
year we granted a total of almost
EUR 900,000 in subsidies to hos-
pital districts for forensic psychi-
atric examinations of children
and adolescents associated with
preliminary criminal investiga-
tions. These concerned forensic
psychiatric examinations of ado-
lescents under the age of 16 and
children, where requested by
courts or prosecuting authorities
in cases where sexual abuse or as-
sault.
But let’s go back to that to
which I was referring to at the
beginning, statements of mental
state of health and withdrawals
of rights to practise a profession.
Last year we issued over 130
statements of mental state of
health to the courts. In compli-
ance with our job description as
extended in October we also
made assessments of the danger
posed by offenders who, having
been sentenced to serve an entire
term and who, after having
served 5/6 of it, have applied for
a release on parole. We restricted
or withdrew the right to practise
professionally of 24 health care
professionals. We also focused
our attention on 43 cases, issued
a notice in 26 cases and a written
warning to four professionals.
When I moved from the Com-
munications Department of the
Ministry of Social Affairs and
Health a couple of months ago to
become an Information Officer at
TEO, people wondered why I left
a hectic observation post and
chose to join TEO. I was even of-
fered a police badge and a gun as
a working tool in this supervisory
police office. I can assure you
that I have arrived in a dynamic,
growing office with challenges in
the ever-varying field of health
care and probably in the future
also in the field of social care,
and these are challenges which
are not by any means small.
Tarja Tamminen
Information Officer
TEO
